Marketdash
Back to News

Burning Rock Shares Surge Over 35% as Cancer Diagnostics Firm Narrows Losses

MarketDash Editorial Team
10 days ago
The Chinese cancer diagnostics company saw its stock jump a third in a week after reporting improved margins and a sharply narrower loss, though its core business remains sluggish. With shares still trading well below their 2021 highs, investors seem to be betting the company is finally approaching profitability.

It's been a remarkable year for certain Chinese stocks, and cancer diagnostics company Burning Rock Biotech Ltd. (BNR) is emerging as one of the more intriguing success stories. The company's shares have tripled in 2025, with the latest surge coming after its third-quarter earnings report sent the stock up about a third in just five trading days to a two-year high and a market cap of $230 million.

Here's the thing, though: Burning Rock has been losing money steadily since its 2020 New York IPO, and its revenue growth hasn't exactly been lighting the world on fire. So what gives?

The company belongs to what we might call the "China Easter Eggs" category—overlooked names with solid fundamentals that investors simply forgot about. But unlike some of those rediscoveries, Burning Rock's investment thesis requires a bit more squinting. The best explanation for the rally seems to be a combination of enviably high gross margins that beat global competitors, plus growing signs the company might actually reach profitability sometime soon.

The Numbers Tell a Mixed Story

Burning Rock's third-quarter results showed the company is making progress, even if it's not exactly a straight line upward. Revenue rose 2.3% year-over-year to 131.6 million yuan from 128.6 million yuan, which doesn't sound thrilling until you dig into what's happening underneath.

The company makes cancer diagnostic products for two markets: in-hospital testing through partner hospitals, and at-home testing kits that individuals can order. The at-home business carries higher margins but has been struggling for the past two years. Why? A government crackdown on medical device companies paying doctors for referrals. Doctors became a lot less enthusiastic about recommending at-home tests once the financial incentives disappeared.

Burning Rock tried pivoting harder toward its in-hospital business, which isn't affected by the crackdown. That strategy was working until this quarter, when in-hospital revenue fell 17.1% year-over-year to 52.8 million yuan from 63.8 million yuan. The company only cited a "decrease in sales volume" without elaborating, and there's no way to press management on it—they discontinued quarterly earnings calls last year.

The at-home testing business, which the company calls its "central lab" operation, also dropped 7.9% to 36.8 million yuan as the lingering effects of the crackdown continue.

The Bright Spot: R&D Services

What saved the quarter was a 69% explosion in R&D services revenue, which jumped to 42 million yuan from 24.9 million yuan. That looks like a potential new growth engine, except there's a catch: this revenue stream is notoriously volatile and can swing dramatically from quarter to quarter. Looking back at recent reports, you see big jumps followed by equally significant declines. So while it's encouraging, it's not exactly a reliable foundation to build on.

Those Impressive Margins

Here's where Burning Rock really shines. The company's gross margin hit 75.1% in the third quarter, up nearly 4 percentage points from 71.4% a year earlier. That's genuinely impressive. France's bioMérieux posted a gross margin of 56.3% over the last 12 months, while the much larger Thermo Fisher Scientific came in at just 41.3%.

The problem is that high gross margins don't mean much if your operating expenses eat up all the gains. Burning Rock's expenses totaled 115 million yuan in the quarter—about 87% of revenue. That's down 12% year-over-year, which is progress, but still substantial enough to keep the company in the red.

The good news? The net loss narrowed dramatically to 16.8 million yuan from 35.7 million yuan a year earlier. That's the kind of improvement that makes investors think profitability might actually be on the horizon. Plus, a significant portion of the company's expenses come from non-cash items like stock-based compensation and depreciation, which means there's no immediate cash crunch looming.

Valuation Still Looks Reasonable

Even after tripling this year, Burning Rock trades at a price-to-sales ratio of 3.0, which is close to bioMérieux's 3.17 and well below Thermo Fisher Scientific's 5.14. And despite the recent rally, the stock still trades at less than a tenth of the highs it reached in 2021 shortly after its IPO. That suggests either the market is still undervaluing the company, or those 2021 prices were completely detached from reality. Probably some of both.

International Expansion Hits Turbulence

There was one positive international development: Japan approved some of Burning Rock's products as "companion diagnostics" for capivasertib, an oral breast cancer drug from AstraZeneca. But even that silver lining has a cloud. The company's non-China revenue dropped to just 17.2 million yuan in the third quarter from 25.8 million yuan a year earlier. So much for global expansion.

Part of a Broader Pattern

Burning Rock isn't alone in this overlooked-to-discovered journey. Other Chinese stocks that have caught fire this year include wearable device maker Zepp (ZEPP), up tenfold since January, So-Young (SY), which has tripled, and Here Group (HERE), formerly QuantaSing, up 150%.

The difference is that those companies had relatively clear growth catalysts that investors simply missed. Burning Rock's case is murkier. The core business is solid enough but isn't exactly rocketing forward. There aren't any obvious major catalysts waiting in the pipeline.

The Bottom Line

What we're left with is a company that's improving but not transforming. The high gross margins are genuinely impressive and suggest a quality business model. The narrowing losses point toward eventual profitability, which would be a meaningful milestone. And the valuation still looks reasonable by most measures.

But the core business remains sluggish, international expansion is struggling, and the one bright spot—R&D services—has proven too inconsistent to count on. Investors bidding up the stock by a third in a week seem to be betting that the path to profitability will unlock value that's been hiding in plain sight. Maybe they're right. Or maybe they're just excited to finally notice a stock that's been sitting there all along, waiting for someone to pay attention.

Back to News

Burning Rock Shares Surge Over 35% as Cancer Diagnostics Firm Narrows Losses

MarketDash Editorial Team
10 days ago
The Chinese cancer diagnostics company saw its stock jump a third in a week after reporting improved margins and a sharply narrower loss, though its core business remains sluggish. With shares still trading well below their 2021 highs, investors seem to be betting the company is finally approaching profitability.

It's been a remarkable year for certain Chinese stocks, and cancer diagnostics company Burning Rock Biotech Ltd. (BNR) is emerging as one of the more intriguing success stories. The company's shares have tripled in 2025, with the latest surge coming after its third-quarter earnings report sent the stock up about a third in just five trading days to a two-year high and a market cap of $230 million.

Here's the thing, though: Burning Rock has been losing money steadily since its 2020 New York IPO, and its revenue growth hasn't exactly been lighting the world on fire. So what gives?

The company belongs to what we might call the "China Easter Eggs" category—overlooked names with solid fundamentals that investors simply forgot about. But unlike some of those rediscoveries, Burning Rock's investment thesis requires a bit more squinting. The best explanation for the rally seems to be a combination of enviably high gross margins that beat global competitors, plus growing signs the company might actually reach profitability sometime soon.

The Numbers Tell a Mixed Story

Burning Rock's third-quarter results showed the company is making progress, even if it's not exactly a straight line upward. Revenue rose 2.3% year-over-year to 131.6 million yuan from 128.6 million yuan, which doesn't sound thrilling until you dig into what's happening underneath.

The company makes cancer diagnostic products for two markets: in-hospital testing through partner hospitals, and at-home testing kits that individuals can order. The at-home business carries higher margins but has been struggling for the past two years. Why? A government crackdown on medical device companies paying doctors for referrals. Doctors became a lot less enthusiastic about recommending at-home tests once the financial incentives disappeared.

Burning Rock tried pivoting harder toward its in-hospital business, which isn't affected by the crackdown. That strategy was working until this quarter, when in-hospital revenue fell 17.1% year-over-year to 52.8 million yuan from 63.8 million yuan. The company only cited a "decrease in sales volume" without elaborating, and there's no way to press management on it—they discontinued quarterly earnings calls last year.

The at-home testing business, which the company calls its "central lab" operation, also dropped 7.9% to 36.8 million yuan as the lingering effects of the crackdown continue.

The Bright Spot: R&D Services

What saved the quarter was a 69% explosion in R&D services revenue, which jumped to 42 million yuan from 24.9 million yuan. That looks like a potential new growth engine, except there's a catch: this revenue stream is notoriously volatile and can swing dramatically from quarter to quarter. Looking back at recent reports, you see big jumps followed by equally significant declines. So while it's encouraging, it's not exactly a reliable foundation to build on.

Those Impressive Margins

Here's where Burning Rock really shines. The company's gross margin hit 75.1% in the third quarter, up nearly 4 percentage points from 71.4% a year earlier. That's genuinely impressive. France's bioMérieux posted a gross margin of 56.3% over the last 12 months, while the much larger Thermo Fisher Scientific came in at just 41.3%.

The problem is that high gross margins don't mean much if your operating expenses eat up all the gains. Burning Rock's expenses totaled 115 million yuan in the quarter—about 87% of revenue. That's down 12% year-over-year, which is progress, but still substantial enough to keep the company in the red.

The good news? The net loss narrowed dramatically to 16.8 million yuan from 35.7 million yuan a year earlier. That's the kind of improvement that makes investors think profitability might actually be on the horizon. Plus, a significant portion of the company's expenses come from non-cash items like stock-based compensation and depreciation, which means there's no immediate cash crunch looming.

Valuation Still Looks Reasonable

Even after tripling this year, Burning Rock trades at a price-to-sales ratio of 3.0, which is close to bioMérieux's 3.17 and well below Thermo Fisher Scientific's 5.14. And despite the recent rally, the stock still trades at less than a tenth of the highs it reached in 2021 shortly after its IPO. That suggests either the market is still undervaluing the company, or those 2021 prices were completely detached from reality. Probably some of both.

International Expansion Hits Turbulence

There was one positive international development: Japan approved some of Burning Rock's products as "companion diagnostics" for capivasertib, an oral breast cancer drug from AstraZeneca. But even that silver lining has a cloud. The company's non-China revenue dropped to just 17.2 million yuan in the third quarter from 25.8 million yuan a year earlier. So much for global expansion.

Part of a Broader Pattern

Burning Rock isn't alone in this overlooked-to-discovered journey. Other Chinese stocks that have caught fire this year include wearable device maker Zepp (ZEPP), up tenfold since January, So-Young (SY), which has tripled, and Here Group (HERE), formerly QuantaSing, up 150%.

The difference is that those companies had relatively clear growth catalysts that investors simply missed. Burning Rock's case is murkier. The core business is solid enough but isn't exactly rocketing forward. There aren't any obvious major catalysts waiting in the pipeline.

The Bottom Line

What we're left with is a company that's improving but not transforming. The high gross margins are genuinely impressive and suggest a quality business model. The narrowing losses point toward eventual profitability, which would be a meaningful milestone. And the valuation still looks reasonable by most measures.

But the core business remains sluggish, international expansion is struggling, and the one bright spot—R&D services—has proven too inconsistent to count on. Investors bidding up the stock by a third in a week seem to be betting that the path to profitability will unlock value that's been hiding in plain sight. Maybe they're right. Or maybe they're just excited to finally notice a stock that's been sitting there all along, waiting for someone to pay attention.